Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intranasal zolmitriptan.

Marek Gawel1, Irene Worthington

  • 1Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada. marek.gawel@sw.ca

Expert Opinion on Pharmacotherapy
|June 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial.

European heart journal·2016
Same author

Canadian Headache Society Guideline: acute drug therapy for migraine headache.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2013
Same author

Canadian Headache Society guideline for migraine prophylaxis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2012
Same author

Botulinum toxin type A and acute drug costs in migraine with triptan overuse.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2010
Same author

Are statin medications safe in patients with ALS?

Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·2008
Same author

Migraine treatment.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2007
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Intranasal zolmitriptan offers rapid migraine relief, showing effectiveness within minutes. This novel formulation ensures quick absorption and action at targeted brain receptors for faster symptom control.

Area of Science:

  • Pharmacology
  • Neurology
  • Drug Delivery Systems

Background:

  • Zolmitriptan is an established antimigraine medication, primarily used orally.
  • A novel intranasal formulation of zolmitriptan has been introduced in the US and Canada.
  • Intranasal administration aims to improve upon the pharmacokinetic profile of oral zolmitriptan.

Purpose of the Study:

  • To review initial studies on intranasal zolmitriptan.
  • To examine the rapid absorption and onset of action of this new formulation.
  • To detail findings from recent clinical investigations of intranasal zolmitriptan.

Main Methods:

  • Review of pharmacokinetic studies assessing absorption and brain penetration.
  • Analysis of clinical trial data, including the REALIZE study.

Related Experiment Videos

  • Examination of efficacy data based on time to symptom relief.

    • Main Results:

    • Intranasal zolmitriptan demonstrates rapid systemic absorption, with drug traces detected in the brain within 5 minutes.
    • Onset of efficacy was observed as early as 10-15 minutes in clinical studies.
    • The formulation targets 5-HT(1B/1D) receptors, consistent with zolmitriptan's mechanism of action.

    Conclusions:

    • Intranasal zolmitriptan provides a faster onset of action compared to oral formulations.
    • The rapid absorption and early efficacy support its use for acute migraine treatment.
    • This novel formulation represents a significant advancement in migraine management delivery.